Pediatric Clinical Trials Market
Market Insights on Pediatric Clinical Trials Market covering sales outlook, demand forecast & up-to-date key trends
Pediatric Clinical Trials Market by Phase Type, Study Design, Therapeutic Areas & Region - Forecast 2022 – 2032
Pediatric Clinical Trials Market Snapshot (2022-2032)
[307 Pages Report] According to Future Market Insights, the global pediatric clinical trials Market is projected to grow steadily at a 5.3% value CAGR, during the forecast period 2022-2032. Earlier in 2021, this market was projected to have a global market valuation worth US$ 15 Billion and is expected to reach a sum of US$ 26.47 Billion by 2032.
|
Global Growth Rate (2022-2032) |
5.3% CAGR |
|
Estimated Market Value in 2021 |
US$ 15 Billion |
|
Projected Market Value in 2022 |
US$ 15.8 Billion |
|
Projected Market Value by 2032 |
US$ 26.47 Billion |
Due to unmet healthcare needs in the pediatric patient population, there is a considerable product pipeline in the clinical phase of development. In the foreseeable future, the market will benefit from a robust medication development pipeline. Furthermore, in 2021, there were over 1,300 industry-sponsored pediatric clinical studies underway spanning a wide range of therapeutic categories, including communicable diseases, genetic disorders, neurologic issues, and numerous types of cancer.
Increasing pediatric medicine awareness, outsourcing in-house clinical trials to CROs, and the Increasing Burden of Pediatric Diseases such as Diabetes are projected to drive market growth globally. By region, North America is observed to have a substantial proportion of the pediatric clinical trial market, and this trend is projected to continue during the projection period.
The United States has the region's most lucrative market. The rising prevalence of disorders in the country's pediatric population is strengthening research initiatives to produce particular medications and expanding the number of clinical trials. This, together with other factors, is driving demand for the worldwide pediatric clinical trials market.
Let us know your requirement to get
100% FREE customization
Prominent Growth Drivers Influencing Pediatric Clinical Trials Industry
Increased Incidence of Chronic Diseases to accelerate Market Growth
The growing demand for innovative vaccines and biological products to treat infectious illnesses such as measles, polio, mumps, TB, rubella, influenza, whooping cough, chickenpox, malaria, and staphylococcus pharyngitis is likely to fuel market expansion. According to the World Health Organization (WHO) 2021, over 85 percent of infants worldwide are vaccinated against 27 illnesses; yet, 19.4 million children are unvaccinated, resulting in the deaths of 2-3 million children per year. According to the Centers for Disease Control and Prevention (CDC) fact page, in 2021, over 471,000 children in the United States had active epilepsy, accounting for approximately 0.6 percent of children aged 0-17 years.
At the same time, diabetes is a major concern among children nowadays. According to the International Diabetes Federation's (IDF) Diabetes Atlas 2021, around 464 million children globally had diabetes in 2021. One million of these people (children and adolescents under the age of 20) have type 1 diabetes.
Rising parental awareness of pediatric clinical trials for dangerous infections and chronic disorders, as well as a substantial number of CROs performing pediatric studies, are driving the market. Autism is one of the most frequent childhood disorders. According to the CDC, one in every 44 children in the United States will have autism by 2021. The increased prevalence of autism among children is expected to propel the market for autism clinical trials, promoting pediatric clinical market growth globally.
Shifting In-house Clinical Trials to CROs to augment the market growth
The pharmaceutical business has increasingly shifted from in-house clinical research to contract research organizations during the previous decade (CRO). According to the Tufts University in association with ICON PLC on CRO strategic alliances, it is anticipated that by 2022, 72% of all clinical trials would have been moved to CROs worldwide. CROs' roles are becoming more crucial as they get more active in clinical research and are viewed as more considered partners, offering access not only to devoted experts but also to patients all over the world.
Both the Food and drug administration and the European Medicines Agency (EMA) have made significant revisions to their standards, and most clinical studies now require a pediatric component. The expansion of these pediatric studies has also resulted in the establishment of pediatric CROs, such as Paidion Research, the first global CRO dedicated solely to pediatric health research. Many CROs are merging in order to raise their profiles and improve their services. Synteract, for example, bought Pediatric CRO KinderPharm to bolster its pediatric development center, which provides pharmacometric modeling and clinical trial simulation technology, as well as juvenile formulation and toxicological services. Such advancements in CROs have fueled the practice of outsourcing in-house clinical trials to CROs.
What could possibly hinder Pediatric Clinical Trials Deployment?
Strict Regulations during the Pandemic and Risk among Children will restrict the Market’s Growth
Pediatric clinical studies were suspended during the pandemic to limit virus spread. This had an impact on the recruitment of young patients for new clinical studies. Such occurrences are likely to have a detrimental impact on market growth.
The high termination rate of pediatric clinical trials for a variety of reasons is projected to stifle expansion in the pediatric clinical trials market. Pediatric studies have a high failure rate due to factors such as patient accrual. Other concerns include behavioral issues and trial conduct issues such as improper dosing, formulation difficulty, and informative termination, as well as regulatory issues and medication toxicity during clinical studies. According to the US Food and Drug Administration, around 30 to 45% of pediatric trials fail to show safety, efficacy, or result in a labeled indication for pediatric use, resulting in their cancellation.
Differences in the acceptable degree of risk to which children may be exposed in clinical studies are also a problem. The requirement to preserve equipoise within study arms by balancing risks across groups complicates study design, enrollment, and patient consent. When this is done, the choice to enroll a child in a clinical study can be made on the same risk/benefit basis as the non research alternative for care. In reality, regulatory rules in the United States limit the permitted risk exposure for children when there is no recognized direct benefit to them from participating in the study. Furthermore, when direct benefits are possible for a certain study, constraints are placed on the basis for risk exposure. These are going to be some of the serious concerns for the key players in the market.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystComparative View of Pediatric Clinical Trials Market
Pediatric Clinical Trials Market:
|
Attributes |
Pediatric Clinical Trials Market |
|
CAGR (2022-2032) |
5.3% |
|
Market Value (2032) |
US$ 18.44 Billion |
|
Growth Factor |
Increasing R&D investments by the pharmaceutical industry as a result of the high burden of chronic conditions among pediatrics, as well as the COVID-19 pandemic, have contributed significantly to the demand for the pediatric clinical trials market. |
|
Opportunity |
Decentralized trials have been gradually adopted to ease pediatric trials. Such collaborations are projected to accelerate pediatric clinical trials and enhance the adoption of decentralized trials. |
|
Key Trends |
The Australian Government's Medical Research Future Fund (MRFF) awarded the researchers USD 1.8 million in May 2022 to discover a therapy for juvenile idiopathic arthritis. Such measures help to grow the pediatric clinical trial market. |
Omics Based Clinical Trials Market:
|
Attributes |
Omics Based Clinical Trials Market |
|
CAGR (2022-2032) |
8.1% |
|
Market Value (2032) |
US$ 61.71 Billion |
|
Growth Factor |
The Covid-19 pandemic, rising investment in the pharmaceutical sector by prominent participants to increase productivity, and the increasing frequency of chronic illnesses are the primary drivers of the increasing demands for omics-based clinical trials. |
|
Opportunity |
The single-cell multi-OMIC analysis is a breakthrough method that is advancing cancer medication research and therapeutic options. A growing number of biologics, the need for innovative technologies, and the demand for personalized treatments and orphan drugs are paving new avenues for this market. |
|
Key Trends |
In December, 2021, Rebus Biosystems Inc., a life science technology enterprise based in the United States, had acquired the assay assets and intellectual property of EEL Transcriptomics AB, a privately held company specialized on high-plex spatial transcriptomics with single-cell resolution. |
Clinical Trial Logistics Market:
|
Attributes |
Clinical Trial Logistics Market |
|
CAGR (2022-2032) |
7.2% |
|
Market Value (2032) |
US$ 6.45 Billion |
|
Growth Factor |
The increasing number of clinical trials done internationally, as well as technological advances in the supply chain, are likely to boost the global Clinical Trial Logistics Market. |
|
Opportunity |
This industry employs innovative IT systems that are adaptable enough to accommodate a wide range of changes. To fulfill rising demand, new umbrella, basket, and platform trials are being conducted, supplies are being pooled, and more sophisticated logistical and shelf-life challenges are being considered. |
|
Key Trends |
Technological advancements are having a favorable impact on the global market, both inbound and outward. As more Point of Care (POC) diagnostic technologies are created, there will be a tendency toward performing more local analysis and sending fewer blood, tissue, urine, and other samples to a central site for assessment. |
Category-wise Insights
Which Phase insight is forecast to gain the Maximum Market Share?
Phase-II Clinical Trials likely to gain maximum share
Phase II trials category dominates the market, accounting for more than 33% of global revenue. Phase II clinical studies are designed to determine the pharmacological efficacy of new medicines. They are usually single-arm experiments, although they can also be multi-arm trials. Multiple-arm trials with or without control arms might be randomized or nonrandomized.
Children are subjected to phase II trials to examine the intervention's safety and efficacy. Phase II research includes a large number of pediatric individuals; also, studies in this stage are more sophisticated than those in previous phases. Generally, testing of pharmaceutical products in children is postponed until the trials reach phase III, which investigates efficacy, acceptability, and safety.
Although the deferral is intended to protect children from harm, it also indicates that children's access to potentially beneficial treatments will be delayed. Phase II trials have been shown to have higher success rates and are increasingly being conducted in the market due to their superior efficacy.
By Study Design, which Category is likely to benefit the most?
The Treatment Studies Segment is forecast to grow in the future
Treatment studies account for more than 66% of the global market's revenue. According to Clinicaltrials.gov, 63,060 pediatric trials were filed between 2001 and 2021, with 37,136 (68.1 percent) containing therapy studies. There were fewer drug studies conducted throughout time, although the majority of therapy pediatric trials were single site (61.4 percent), small-scale (58.9 percent), randomized (66.0 percent), and had no masking (56.9 percent).
Institutions (78.8 percent), industry (19.1 percent), NIH (National Institute of Health) (1.6 percent), and U.S. public agencies fund the majority of pediatric trial treatment studies (0.5 percent). This is one of the primary causes for the segment's rapid growth in the global market.
Which Therapeutic Area will gain prominence during the Forecast Period?
Oncology is expected to be the fastest growing during the forecast period
By therapeutics, oncology is expected to hold a high revenue share of more than 17% of the global market. Cancer is a leading cause of death worldwide. Cancer cases among youngsters under the age of 19 years are expected to reach 291,000 by 2040.
As per the American Cancer Society, an estimated 10,500 children under the age of 15 in the United States will be diagnosed with cancer in 2022. It also claims that pediatric cancer rates have risen in recent decades. Furthermore, According to clinicaltrials.gov, there were roughly 3,287 ongoing pediatric clinical trials for cancer in July 2021. The increased number of these trials is projected to boost the market.
The National Cancer Institute established the Molecular Characterization Initiative for Pediatric Tumors in March 2022. The Initiative is provided by the NCI's Childhood Cancer Data Initiative, which was established to encourage data exchange and the collecting of new data among pediatric oncology experts. With the growing number of pediatric cancer cases globally, many hospitals and institutions are focusing on the development of therapeutic medications, resulting in an increase in the number of pediatric clinical trials worldwide.
An unified Market Research Subscription Platform, built for today’s disparate research needs.
Country-wise Analysis
What is the Outlook of the North American pediatric clinical trials Market?
Increasing chronic diseases among the children in this region will drive this market
North America led the global pediatric clinical trials market, accounting for 45% of global sales. This is owing to the presence of a large number of pharmaceutical companies and contract research organizations (CROs) performing pediatric studies in the region.
The United States is predicted to have a considerable market share and to exhibit a similar trend during the projection period. According to clinicaltrials.gov, there were more than 1,365 ongoing pediatric clinical trials in the United States as of March 2022, representing a significant fraction of the global number of pediatric research operations. The high number of trials, as well as the high cost per treatment and patient, have had a significant impact on the market in the United States.
The rising prevalence of disorders in the country's pediatric population is strengthening research initiatives to produce particular medications and increasing the number of clinical trials. According to the National Diabetes Statistics Report 2021, an estimated 185,000 American children and adolescents were seen to be suffering from Type 1 diabetes in 2020, and this figure is expected to rise in the future years. This will necessitate rapid demand in this industry to combat these diseases.
Aside from that, public groups are taking active steps to fund pediatric research. For example, the current NIH funding for pediatric research is USD 4 billion. Such measures will contribute to the expansion of the market in this region.
How is the growth of pediatric clinical trials emerging in the APAC region?
Huge population with varied genetic defects in the APAC region to boost the market
Asia Pacific is expected to grow at the fastest rate over the forecast period, with a 25% market share. Due to the simplicity of regulatory compliance, low study expenses, and rapidly growing pediatric patient population, the Asia Pacific region has become a hotspot for conducting clinical trials.
APAC has a genetically varied population of approximately 4 billion individuals, many of whom may be treatment-naive in nations such as India and China. As a result, recruiting pediatric patients who match qualifying criteria may be simpler than in Western countries. Furthermore, APAC countries frequently have a big number of desirable patients who show lifestyle-related health and genetic disorders that were previously more widespread in the Western world. In India, for example, children are still born with a variety of genetic abnormalities and chronic diseases.
Furthermore, due to the high frequency of pediatric disorders, supportive activities boosting pediatric research in the region are propelling the regional market. For example, UNESCO reported in March 2022 that China is focusing on creating improvements in neuroscience to treat children with autism in the country.
Region-wise Market Share for the Pediatric Clinical Trials Market
|
North America |
45% |
|
APAC |
25% |
|
Europe |
15% |
|
Latin America |
9% |
|
Middle East & Africa |
6% |
Competitive Landscape
Due to the sheer presence of a few important players in the market with very few additional participants, the industry studied is consolidated. Market participants' primary strategies included trial initialization, acquisitions, and collaborations, among others.
- Pfizer began a Phase 2/3 research for PAXLOVID tablets, which are especially intended to treat COVID-19 in young patients, in March 2022. PAXLOVID reduced the risk of hospitalization or death from any cause by 89 percent (within three days of symptom start) and 88 percent (within five days of appearance of symptoms).
- Novartis announced intentions to begin SMART, a Phase 3b clinical research to assess the safety and efficacy of Zolgensma (onasemnogene abeparvovec) in young children with spinal muscular atrophy, in April 2021. SMART is a multicenter, Phase 3b, single-arm, open-label study designed to assess the safety, tolerability, and efficacy of a one-time IV infusion of Zolgensma in pediatric patients with symptomatic SMA who have bi-allelic genetic changes in the SMN1 gene and any copy number of the SMN2 gene and weigh between 8.5 kg and 21 kg. The study will enroll 24 patients and will monitor them for a 12-month period.
Report Scope
|
Report Attribute |
Details |
|
Growth Rate |
CAGR of 5.3% from 2022 to 2032 |
|
Market Value for 2022 |
US$ 15.8 Billion |
|
Market Value for 2032 |
US$ 26.47 Billion |
|
Base Year for Estimation |
2021 |
|
Historical Data |
2017-2021 |
|
Forecast Period |
2022-2032 |
|
Quantitative Units |
USD Billion for Value |
|
Report Coverage |
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
|
Segments Covered |
|
|
Regions Covered |
|
|
Key Countries Profiled |
|
|
Key Companies Profiled |
|
|
Report Customization & Pricing |
Available upon Request |
Key Segments Covered in the Pediatric Clinical Trials Market Report
Pediatric Clinical Trials Market by Phase Type:
- Phase I Pediatric Clinical Trials
- Phase II Pediatric Clinical Trials
- Phase III Pediatric Clinical Trials
- Phase IV Pediatric Clinical Trials
Pediatric Clinical Trials Market by Study Design:
- Treatment Studies of Pediatric Clinical Trials
- Observational Studies of Pediatric Clinical Trials
Pediatric Clinical Trials Market by Therapeutic Areas:
- Pediatric Clinical Trials for Infectious Diseases
- Pediatric Clinical Trials for Oncology
- Pediatric Clinical Trials for Autoimmune/Inflammatory Diseases
- Pediatric Clinical Trials for Respiratory Disorders
- Pediatric Clinical Trials for Mental Health Disorders
- Pediatric Clinical Trials for Other Therapeutic Areas
Pediatric Clinical Trials Market by Region:
- North American Pediatric Clinical Trials Market
- Europe Pediatric Clinical Trials Market
- Asia Pacific Pediatric Clinical Trials Market
- Middle East & African Pediatric Clinical Trials Market
- Latin America Pediatric Clinical Trials Market
Frequently Asked Questions
From 2017-2021, the pediatric clinical trials Market grew at a CAGR of 5%.
The global pediatric clinical trials Market is expected to grow with a 5.3% CAGR and is projected to gain a market size of US$ 26.47 Billion by 2032
In 2021, the treatment studies segment dominated the global market with 66% market share
The phase II trials segment is expected to occupy a global market share of 33%
The North American pediatric clinical trials market will hold a 45% global market share
APAC is expected to acquire a global market share of 25% in 2021.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Product Life Cycle Analysis
3.5. Investment Feasibility Matrix
3.6. PESTLE and Porter’s Analysis
3.7. Regulatory Landscape
3.7.1. By Key Regions
3.7.2. By Key Countries
3.8. Regional Parent Market Outlook
4. Global Pediatric Clinical Trials Market Analysis 2017-2021 and Forecast, 2022-2032
4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2021
4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Pediatric Clinical Trials Market Analysis 2017-2021 and Forecast 2022-2032, By Phase
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Mn) Analysis By Phase, 2017-2021
5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Phase, 2022-2032
5.3.1. Phase I
5.3.2. Phase II
5.3.3. Phase III
5.3.4. Phase IV
5.4. Y-o-Y Growth Trend Analysis By Phase, 2017-2021
5.5. Absolute $ Opportunity Analysis By Phase, 2022-2032
6. Global Pediatric Clinical Trials Market Analysis 2017-2021 and Forecast 2022-2032, By Study Design
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Mn) Analysis By Study Design, 2017-2021
6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Study Design, 2022-2032
6.3.1. Treatment Studies
6.3.2. Observational Studies
6.4. Y-o-Y Growth Trend Analysis By Study Design, 2017-2021
6.5. Absolute $ Opportunity Analysis By Study Design, 2022-2032
7. Global Pediatric Clinical Trials Market Analysis 2017-2021 and Forecast 2022-2032, By Therapeutic Areas
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Mn) Analysis By Therapeutic Areas, 2017-2021
7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Therapeutic Areas, 2022-2032
7.3.1. Infectious Diseases
7.3.2. Oncology
7.3.3. Autoimmune / Inflammatory Diseases
7.3.4. Respiratory Disorders
7.3.5. Mental Health Disorders
7.3.6. Others
7.4. Y-o-Y Growth Trend Analysis By Therapeutic Areas, 2017-2021
7.5. Absolute $ Opportunity Analysis By Therapeutic Areas, 2022-2032
8. Global Pediatric Clinical Trials Market Analysis 2017-2021 and Forecast 2022-2032, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2017-2021
8.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa
8.4. Market Attractiveness Analysis By Region
9. North America Pediatric Clinical Trials Market Analysis 2017-2021 and Forecast 2022-2032, By Country
9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
9.2.1. By Country
9.2.1.1. U.S.
9.2.1.2. Canada
9.2.2. By Phase
9.2.3. By Study Design
9.2.4. By Therapeutic Areas
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Phase
9.3.3. By Study Design
9.3.4. By Therapeutic Areas
9.4. Key Takeaways
10. Latin America Pediatric Clinical Trials Market Analysis 2017-2021 and Forecast 2022-2032, By Country
10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Phase
10.2.3. By Study Design
10.2.4. By Therapeutic Areas
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Phase
10.3.3. By Study Design
10.3.4. By Therapeutic Areas
10.4. Key Takeaways
11. Europe Pediatric Clinical Trials Market Analysis 2017-2021 and Forecast 2022-2032, By Country
11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. Italy
11.2.1.3. France
11.2.1.4. U.K.
11.2.1.5. Russia
11.2.1.6. BENELUX
11.2.1.7. Rest of Europe
11.2.2. By Phase
11.2.3. By Study Design
11.2.4. By Therapeutic Areas
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Phase
11.3.3. By Study Design
11.3.4. By Therapeutic Areas
11.4. Key Takeaways
12. Asia Pacific Pediatric Clinical Trials Market Analysis 2017-2021 and Forecast 2022-2032, By Country
12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
12.2.1. By Country
12.2.1.1. China
12.2.1.2. Japan
12.2.1.3. South Korea
12.2.1.4. Rest of Asia Pacific
12.2.2. By Phase
12.2.3. By Study Design
12.2.4. By Therapeutic Areas
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Phase
12.3.3. By Study Design
12.3.4. By Therapeutic Areas
12.4. Key Takeaways
13. Middle East and Africa Pediatric Clinical Trials Market Analysis 2017-2021 and Forecast 2022-2032, By Country
13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
13.2.1. By Country
13.2.1.1. GCC Countries
13.2.1.2. South Africa
13.2.1.3. Turkey
13.2.1.4. Rest of Middle East and Africa
13.2.2. By Phase
13.2.3. By Study Design
13.2.4. By Therapeutic Areas
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Phase
13.3.3. By Study Design
13.3.4. By Therapeutic Areas
13.4. Key Takeaways
14. Key Countries Pediatric Clinical Trials Market Analysis
14.1. U.S.
14.1.1. Pricing Analysis
14.1.2. Market Share Analysis, 2021
14.1.2.1. By Phase
14.1.2.2. By Study Design
14.1.2.3. By Therapeutic Areas
14.2. Canada
14.2.1. Pricing Analysis
14.2.2. Market Share Analysis, 2021
14.2.2.1. By Phase
14.2.2.2. By Study Design
14.2.2.3. By Therapeutic Areas
14.3. Brazil
14.3.1. Pricing Analysis
14.3.2. Market Share Analysis, 2021
14.3.2.1. By Phase
14.3.2.2. By Study Design
14.3.2.3. By Therapeutic Areas
14.4. Mexico
14.4.1. Pricing Analysis
14.4.2. Market Share Analysis, 2021
14.4.2.1. By Phase
14.4.2.2. By Study Design
14.4.2.3. By Therapeutic Areas
14.5. Germany
14.5.1. Pricing Analysis
14.5.2. Market Share Analysis, 2021
14.5.2.1. By Phase
14.5.2.2. By Study Design
14.5.2.3. By Therapeutic Areas
14.6. Italy
14.6.1. Pricing Analysis
14.6.2. Market Share Analysis, 2021
14.6.2.1. By Phase
14.6.2.2. By Study Design
14.6.2.3. By Therapeutic Areas
14.7. France
14.7.1. Pricing Analysis
14.7.2. Market Share Analysis, 2021
14.7.2.1. By Phase
14.7.2.2. By Study Design
14.7.2.3. By Therapeutic Areas
14.8. U.K.
14.8.1. Pricing Analysis
14.8.2. Market Share Analysis, 2021
14.8.2.1. By Phase
14.8.2.2. By Study Design
14.8.2.3. By Therapeutic Areas
14.9. Russia
14.9.1. Pricing Analysis
14.9.2. Market Share Analysis, 2021
14.9.2.1. By Phase
14.9.2.2. By Study Design
14.9.2.3. By Therapeutic Areas
14.10. BENELUX
14.10.1. Pricing Analysis
14.10.2. Market Share Analysis, 2021
14.10.2.1. By Phase
14.10.2.2. By Study Design
14.10.2.3. By Therapeutic Areas
14.11. China
14.11.1. Pricing Analysis
14.11.2. Market Share Analysis, 2021
14.11.2.1. By Phase
14.11.2.2. By Study Design
14.11.2.3. By Therapeutic Areas
14.12. Japan
14.12.1. Pricing Analysis
14.12.2. Market Share Analysis, 2021
14.12.2.1. By Phase
14.12.2.2. By Study Design
14.12.2.3. By Therapeutic Areas
14.13. South Korea
14.13.1. Pricing Analysis
14.13.2. Market Share Analysis, 2021
14.13.2.1. By Phase
14.13.2.2. By Study Design
14.13.2.3. By Therapeutic Areas
14.14. GCC Countries
14.14.1. Pricing Analysis
14.14.2. Market Share Analysis, 2021
14.14.2.1. By Phase
14.14.2.2. By Study Design
14.14.2.3. By Therapeutic Areas
14.15. South Africa
14.15.1. Pricing Analysis
14.15.2. Market Share Analysis, 2021
14.15.2.1. By Phase
14.15.2.2. By Study Design
14.15.2.3. By Therapeutic Areas
14.16. Turkey
14.16.1. Pricing Analysis
14.16.2. Market Share Analysis, 2021
14.16.2.1. By Phase
14.16.2.2. By Study Design
14.16.2.3. By Therapeutic Areas
15. Market Structure Analysis
15.1. Competition Dashboard
15.2. Competition Benchmarking
15.3. Market Share Analysis of Top Players
15.3.1. By Regional
15.3.2. By Phase
15.3.3. By Study Design
15.3.4. By Therapeutic Areas
16. Competition Analysis
16.1. Competition Deep Dive
16.1.1. ICON plc
16.1.1.1. Overview
16.1.1.2. Product Portfolio
16.1.1.3. Profitability by Market Segments
16.1.1.4. Sales Footprint
16.1.1.5. Strategy Overview
16.1.1.5.1. Marketing Strategy
16.1.2. Syneos Health
16.1.2.1. Overview
16.1.2.2. Product Portfolio
16.1.2.3. Profitability by Market Segments
16.1.2.4. Sales Footprint
16.1.2.5. Strategy Overview
16.1.2.5.1. Marketing Strategy
16.1.3. Medpace, Inc.
16.1.3.1. Overview
16.1.3.2. Product Portfolio
16.1.3.3. Profitability by Market Segments
16.1.3.4. Sales Footprint
16.1.3.5. Strategy Overview
16.1.3.5.1. Marketing Strategy
16.1.4. PPD Inc.
16.1.4.1. Overview
16.1.4.2. Product Portfolio
16.1.4.3. Profitability by Market Segments
16.1.4.4. Sales Footprint
16.1.4.5. Strategy Overview
16.1.4.5.1. Marketing Strategy
16.1.5. Premier Research
16.1.5.1. Overview
16.1.5.2. Product Portfolio
16.1.5.3. Profitability by Market Segments
16.1.5.4. Sales Footprint
16.1.5.5. Strategy Overview
16.1.5.5.1. Marketing Strategy
16.1.6. LabCorp Drug Development
16.1.6.1. Overview
16.1.6.2. Product Portfolio
16.1.6.3. Profitability by Market Segments
16.1.6.4. Sales Footprint
16.1.6.5. Strategy Overview
16.1.6.5.1. Marketing Strategy
16.1.7. QPS Holdings
16.1.7.1. Overview
16.1.7.2. Product Portfolio
16.1.7.3. Profitability by Market Segments
16.1.7.4. Sales Footprint
16.1.7.5. Strategy Overview
16.1.7.5.1. Marketing Strategy
16.1.8. Pfizer Inc.
16.1.8.1. Overview
16.1.8.2. Product Portfolio
16.1.8.3. Profitability by Market Segments
16.1.8.4. Sales Footprint
16.1.8.5. Strategy Overview
16.1.8.5.1. Marketing Strategy
16.1.9. The Emmes Company, LLC
16.1.9.1. Overview
16.1.9.2. Product Portfolio
16.1.9.3. Profitability by Market Segments
16.1.9.4. Sales Footprint
16.1.9.5. Strategy Overview
16.1.9.5.1. Marketing Strategy
16.1.10. IQVIA Inc.
16.1.10.1. Overview
16.1.10.2. Product Portfolio
16.1.10.3. Profitability by Market Segments
16.1.10.4. Sales Footprint
16.1.10.5. Strategy Overview
16.1.10.5.1. Marketing Strategy
17. Assumptions & Acronyms Used
18. Research Methodology
Let us know your requirement to get
100% FREE customization
Table 1: Global Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Region, 2017-2032
Table 2: Global Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Phase, 2017-2032
Table 3: Global Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Study Design, 2017-2032
Table 4: Global Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Therapeutic Areas, 2017-2032
Table 5: North America Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 6: North America Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Phase, 2017-2032
Table 7: North America Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Study Design, 2017-2032
Table 8: North America Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Therapeutic Areas, 2017-2032
Table 9: Latin America Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 10: Latin America Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Phase, 2017-2032
Table 11: Latin America Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Study Design, 2017-2032
Table 12: Latin America Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Therapeutic Areas, 2017-2032
Table 13: Europe Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 14: Europe Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Phase, 2017-2032
Table 15: Europe Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Study Design, 2017-2032
Table 16: Europe Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Therapeutic Areas, 2017-2032
Table 17: Asia Pacific Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 18: Asia Pacific Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Phase, 2017-2032
Table 19: Asia Pacific Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Study Design, 2017-2032
Table 20: Asia Pacific Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Therapeutic Areas, 2017-2032
Table 21: Middle East and Africa Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 22: Middle East and Africa Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Phase, 2017-2032
Table 23: Middle East and Africa Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Study Design, 2017-2032
Table 24: Middle East and Africa Pediatric Clinical Trials Market Value (US$ Mn) Forecast by Therapeutic Areas, 2017-2032
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystFigure 1: Global Pediatric Clinical Trials Market Value (US$ Mn) by Phase, 2022-2032
Figure 2: Global Pediatric Clinical Trials Market Value (US$ Mn) by Study Design, 2022-2032
Figure 3: Global Pediatric Clinical Trials Market Value (US$ Mn) by Therapeutic Areas, 2022-2032
Figure 4: Global Pediatric Clinical Trials Market Value (US$ Mn) by Region, 2022-2032
Figure 5: Global Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Region, 2017-2032
Figure 6: Global Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Region, 2022-2032
Figure 7: Global Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Region, 2022-2032
Figure 8: Global Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Phase, 2017-2032
Figure 9: Global Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Phase, 2022-2032
Figure 10: Global Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Phase, 2022-2032
Figure 11: Global Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Study Design, 2017-2032
Figure 12: Global Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Study Design, 2022-2032
Figure 13: Global Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Study Design, 2022-2032
Figure 14: Global Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Therapeutic Areas, 2017-2032
Figure 15: Global Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Therapeutic Areas, 2022-2032
Figure 16: Global Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Therapeutic Areas, 2022-2032
Figure 17: Global Pediatric Clinical Trials Market Attractiveness by Phase, 2022-2032
Figure 18: Global Pediatric Clinical Trials Market Attractiveness by Study Design, 2022-2032
Figure 19: Global Pediatric Clinical Trials Market Attractiveness by Therapeutic Areas, 2022-2032
Figure 20: Global Pediatric Clinical Trials Market Attractiveness by Region, 2022-2032
Figure 21: North America Pediatric Clinical Trials Market Value (US$ Mn) by Phase, 2022-2032
Figure 22: North America Pediatric Clinical Trials Market Value (US$ Mn) by Study Design, 2022-2032
Figure 23: North America Pediatric Clinical Trials Market Value (US$ Mn) by Therapeutic Areas, 2022-2032
Figure 24: North America Pediatric Clinical Trials Market Value (US$ Mn) by Country, 2022-2032
Figure 25: North America Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 26: North America Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 27: North America Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 28: North America Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Phase, 2017-2032
Figure 29: North America Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Phase, 2022-2032
Figure 30: North America Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Phase, 2022-2032
Figure 31: North America Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Study Design, 2017-2032
Figure 32: North America Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Study Design, 2022-2032
Figure 33: North America Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Study Design, 2022-2032
Figure 34: North America Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Therapeutic Areas, 2017-2032
Figure 35: North America Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Therapeutic Areas, 2022-2032
Figure 36: North America Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Therapeutic Areas, 2022-2032
Figure 37: North America Pediatric Clinical Trials Market Attractiveness by Phase, 2022-2032
Figure 38: North America Pediatric Clinical Trials Market Attractiveness by Study Design, 2022-2032
Figure 39: North America Pediatric Clinical Trials Market Attractiveness by Therapeutic Areas, 2022-2032
Figure 40: North America Pediatric Clinical Trials Market Attractiveness by Country, 2022-2032
Figure 41: Latin America Pediatric Clinical Trials Market Value (US$ Mn) by Phase, 2022-2032
Figure 42: Latin America Pediatric Clinical Trials Market Value (US$ Mn) by Study Design, 2022-2032
Figure 43: Latin America Pediatric Clinical Trials Market Value (US$ Mn) by Therapeutic Areas, 2022-2032
Figure 44: Latin America Pediatric Clinical Trials Market Value (US$ Mn) by Country, 2022-2032
Figure 45: Latin America Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 46: Latin America Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 47: Latin America Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 48: Latin America Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Phase, 2017-2032
Figure 49: Latin America Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Phase, 2022-2032
Figure 50: Latin America Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Phase, 2022-2032
Figure 51: Latin America Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Study Design, 2017-2032
Figure 52: Latin America Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Study Design, 2022-2032
Figure 53: Latin America Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Study Design, 2022-2032
Figure 54: Latin America Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Therapeutic Areas, 2017-2032
Figure 55: Latin America Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Therapeutic Areas, 2022-2032
Figure 56: Latin America Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Therapeutic Areas, 2022-2032
Figure 57: Latin America Pediatric Clinical Trials Market Attractiveness by Phase, 2022-2032
Figure 58: Latin America Pediatric Clinical Trials Market Attractiveness by Study Design, 2022-2032
Figure 59: Latin America Pediatric Clinical Trials Market Attractiveness by Therapeutic Areas, 2022-2032
Figure 60: Latin America Pediatric Clinical Trials Market Attractiveness by Country, 2022-2032
Figure 61: Europe Pediatric Clinical Trials Market Value (US$ Mn) by Phase, 2022-2032
Figure 62: Europe Pediatric Clinical Trials Market Value (US$ Mn) by Study Design, 2022-2032
Figure 63: Europe Pediatric Clinical Trials Market Value (US$ Mn) by Therapeutic Areas, 2022-2032
Figure 64: Europe Pediatric Clinical Trials Market Value (US$ Mn) by Country, 2022-2032
Figure 65: Europe Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 66: Europe Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 67: Europe Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 68: Europe Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Phase, 2017-2032
Figure 69: Europe Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Phase, 2022-2032
Figure 70: Europe Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Phase, 2022-2032
Figure 71: Europe Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Study Design, 2017-2032
Figure 72: Europe Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Study Design, 2022-2032
Figure 73: Europe Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Study Design, 2022-2032
Figure 74: Europe Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Therapeutic Areas, 2017-2032
Figure 75: Europe Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Therapeutic Areas, 2022-2032
Figure 76: Europe Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Therapeutic Areas, 2022-2032
Figure 77: Europe Pediatric Clinical Trials Market Attractiveness by Phase, 2022-2032
Figure 78: Europe Pediatric Clinical Trials Market Attractiveness by Study Design, 2022-2032
Figure 79: Europe Pediatric Clinical Trials Market Attractiveness by Therapeutic Areas, 2022-2032
Figure 80: Europe Pediatric Clinical Trials Market Attractiveness by Country, 2022-2032
Figure 81: Asia Pacific Pediatric Clinical Trials Market Value (US$ Mn) by Phase, 2022-2032
Figure 82: Asia Pacific Pediatric Clinical Trials Market Value (US$ Mn) by Study Design, 2022-2032
Figure 83: Asia Pacific Pediatric Clinical Trials Market Value (US$ Mn) by Therapeutic Areas, 2022-2032
Figure 84: Asia Pacific Pediatric Clinical Trials Market Value (US$ Mn) by Country, 2022-2032
Figure 85: Asia Pacific Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 86: Asia Pacific Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 87: Asia Pacific Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 88: Asia Pacific Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Phase, 2017-2032
Figure 89: Asia Pacific Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Phase, 2022-2032
Figure 90: Asia Pacific Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Phase, 2022-2032
Figure 91: Asia Pacific Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Study Design, 2017-2032
Figure 92: Asia Pacific Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Study Design, 2022-2032
Figure 93: Asia Pacific Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Study Design, 2022-2032
Figure 94: Asia Pacific Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Therapeutic Areas, 2017-2032
Figure 95: Asia Pacific Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Therapeutic Areas, 2022-2032
Figure 96: Asia Pacific Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Therapeutic Areas, 2022-2032
Figure 97: Asia Pacific Pediatric Clinical Trials Market Attractiveness by Phase, 2022-2032
Figure 98: Asia Pacific Pediatric Clinical Trials Market Attractiveness by Study Design, 2022-2032
Figure 99: Asia Pacific Pediatric Clinical Trials Market Attractiveness by Therapeutic Areas, 2022-2032
Figure 100: Asia Pacific Pediatric Clinical Trials Market Attractiveness by Country, 2022-2032
Figure 101: Middle East and Africa Pediatric Clinical Trials Market Value (US$ Mn) by Phase, 2022-2032
Figure 102: Middle East and Africa Pediatric Clinical Trials Market Value (US$ Mn) by Study Design, 2022-2032
Figure 103: Middle East and Africa Pediatric Clinical Trials Market Value (US$ Mn) by Therapeutic Areas, 2022-2032
Figure 104: Middle East and Africa Pediatric Clinical Trials Market Value (US$ Mn) by Country, 2022-2032
Figure 105: Middle East and Africa Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 106: Middle East and Africa Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 107: Middle East and Africa Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 108: Middle East and Africa Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Phase, 2017-2032
Figure 109: Middle East and Africa Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Phase, 2022-2032
Figure 110: Middle East and Africa Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Phase, 2022-2032
Figure 111: Middle East and Africa Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Study Design, 2017-2032
Figure 112: Middle East and Africa Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Study Design, 2022-2032
Figure 113: Middle East and Africa Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Study Design, 2022-2032
Figure 114: Middle East and Africa Pediatric Clinical Trials Market Value (US$ Mn) Analysis by Therapeutic Areas, 2017-2032
Figure 115: Middle East and Africa Pediatric Clinical Trials Market Value Share (%) and BPS Analysis by Therapeutic Areas, 2022-2032
Figure 116: Middle East and Africa Pediatric Clinical Trials Market Y-o-Y Growth (%) Projections by Therapeutic Areas, 2022-2032
Figure 117: Middle East and Africa Pediatric Clinical Trials Market Attractiveness by Phase, 2022-2032
Figure 118: Middle East and Africa Pediatric Clinical Trials Market Attractiveness by Study Design, 2022-2032
Figure 119: Middle East and Africa Pediatric Clinical Trials Market Attractiveness by Therapeutic Areas, 2022-2032
Figure 120: Middle East and Africa Pediatric Clinical Trials Market Attractiveness by Country, 2022-2032
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
